摘要
目的比较培美曲塞二钠及多西紫杉醇加奥沙利铂治疗晚期肺腺癌的临床疗效与不良反应。方法 63例肺腺癌患者,随机分为试验组(培美曲塞+奥沙利铂),对照组(多西紫杉醇+奥沙利铂),21天为1个周期,治疗2个周期后评价疗效。结果入组的63例可评价疗效。试验组及对照组的总有效率分别是40.63%及38.7%(P>0.05)。发生在两组内的不良反应主要表现为骨髓抑制、恶心/呕吐、乏力及皮疹,试验组明显低于对照组(P<0.05)。结论对于晚期肺腺癌患者,使用培美曲塞与多西紫杉醇联合奥沙利铂进行化疗,疗效相似,但使用培美曲塞组不良反应较低。
Objective To investigate the efficacy and safety of pemetrexed plus oxaliplatin compared with docetaxel plus Oxalipla- tin in the treatment of patients with advanced lung adenocarcinoma. Methods 63 advanced adenocarcinoma patients were randomly divid- ed into the test group （ Pemetrexed plus Oxaliplatin） and the control group （ Docetaxel plus Oxaliplatin）. The two groups received these regiments for 2 cycles, and each cycle for 21 days. Results 63 advanced lung adenocarcinoma patients were retrospectively reviewed. The total effective rates were 40. 63% in the test group and 38.7% in the control group （ P 〉 0. 05 ）. The side effects in both groups main- ly were hematologic toxicity, skin rash, gastrointestinal adverse events and fatigue. There was a statistical significance between the two groups （ P 〈 0.05 ）. Conclusion The chemotherapy regimen of pemetrexed plus oxaliplation group is equally effective in the treatment of patients with advanced adenocarcinoma as docetaxel plus oxaliplation, but the incidence of side effects in pemetrexed plus the oxaliplation group is lower than that in the docetaxel plus oxaliplatin group.
出处
《临床肺科杂志》
2013年第3期423-425,共3页
Journal of Clinical Pulmonary Medicine
